Search results for abx831408

Emapalumab, Abbexa, abx831408

Emapalumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IFNG, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. 1, 5 The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy. 5 As well, emapalumab was given the status of PRIME by the EMA.